MDH2 silencing reduces prostate cancer cell growth and enhances docetaxel sensitivity by causing metabolic inefficiency; high MDH2 expression is associated with shorter recurrence-free survival and treatment tolerance in prostate cancer patients [22]. The gene discussed is MDH2; the disease is prostate cancer.